Trials / Unknown
UnknownNCT03919253
Pyrotinib in Combination With Nab-paclitaxel in Patients With HER2-positive Advanced Breast Cancer: an Exploratory Study
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- Sponsor
- Hebei Medical University Fourth Hospital · Academic / Other
- Sex
- Female
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This clinical trial aim to evaluate the efficacy and safety of Pyrotinib in combination with nab-paclitaxel in patients with HER2-positive advanced breast cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| COMBINATION_PRODUCT | pyrotinib maleate tablets+nab-paclitaxel | pyrotinib maleate tablets: 400mg orally once daily continunously nab-paclitaxel: 125mg/m2 iv d1、8 of each 21 day cycle, 6cycles. |
Timeline
- Start date
- 2019-04-30
- Primary completion
- 2020-04-30
- Completion
- 2022-04-30
- First posted
- 2019-04-18
- Last updated
- 2019-04-18
Source: ClinicalTrials.gov record NCT03919253. Inclusion in this directory is not an endorsement.